The Janssen COVID-19 Vaccine is the first single-dose vaccine regimen to ever be granted WHO emergency use listing and is now eligible for distribution via COVAX.
List view / Grid view
Filter the results
The addition of €500 million to the EU’s existing COVAX Facility pledge was announced at the G7 summit virtual leaders' meeting.
The Emergency Use Listing will allow doses of the COVID-19 vaccines to be distributed through COVAX, the WHO’s vaccine allocation facility.
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
Contributing to ACT Accelerator could generate $466 billion for major economies, says Eurasia Group report
The report found that the 10 major economies could see a return of more than $466 billion by 2025, 12 times the total estimated cost of supporting the WHO’s Access to COVID-19 Tools (ACT) Accelerator.
The WHO Regional Director for Africa urges governments to “ramp up readiness” as report suggests the region is not prepared for a COVID-19 vaccine roll-out.
Subject to regulatory approval, EU member states will be supplied with the potentially highly effective BNT162b2 COVID-19 vaccine candidate.
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
The trial will evaluate the safety, tolerability and immunogenicity of the duo’s COVID-19 recombinant protein-based vaccine candidate in 440 healthy US participants.